ITO EN Oi Ocha Green Teas Coming Soon to Walmart
30.7.2019 15:15:00 EEST | Business Wire | Press release
ITO EN (North America) INC. the global leaders of green tea and innovators of healthy beverages today announced that their Oi Ocha ready-to-drink green tea brand, will soon be available in Walmart stores nationwide. Slated for placement in October 2019 with two unsweetened flavors- ITO EN’s premium Oi Ocha green tea, Japan’s top selling brand and Jasmine Green Tea, a popular green tea infused with jasmine flowers. The award-winning teas are celebrated for their naturally smooth taste and clean finish, brewed with ITO EN’s proprietary brewing method using whole tea leaves without artificial additives, flavors or colors, and powders or concentrates. The authentic and refreshing teas are Non-GMO certified with natural catechin tea antioxidants, natural Vitamin C (Ascorbic Acid) and zero calories. Each packaged in a convenient on the go 16.9 fl. oz recyclable PET bottle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190730005425/en/
ITO EN Oi Ocha and Jasmine Green Tea. (Photo: Business Wire)
“With a growing number of consumers looking for authentic and healthy beverages, we could not be more excited to expand Ito En’s tea products into Walmart stores nationwide,” says Jim Hoagland, COO at ITO EN (North America) INC. “With Walmart responding to the growing consumer interest for high-quality, authentic and better-for-you products, we are confident that our traditional unsweetened green teas are a great fit for Walmart and their customers.”
The Oi Ocha brand has been growing exponentially in the U.S. market as consumer demand for authentic and healthier beverages continues to grow across the specialty, mainstream markets, and food service channels. The partnership with Walmart not only broadens ITO EN’s brand awareness and distribution but will also give accessibility to a better-for-you beverage to the everyday consumer. With green tea gaining popularity for its health benefits while consumers seek sugar free beverages, unsweetened Oi Ocha teas are ideal to integrate into daily life.
ITO EN is specifically known for its commitment to tea expertise and sustainable practices that are reflected across all of its award-winning brands. With over 50 years of tea expertise, the company is dedicated to authenticity, preserving its culture while creating global innovation for the tea and beverage industry. ITO EN is proud to have ranked #18 in FORTUNE's top 50 Companies that have made an important social or environmental impact through its profit-making strategy and operations. The company was also awarded a sustainability award for its used tea leaf recycling program, creating innovative products from a eco-friendly synthetic resin made from used tea leaves. For more information on ITO EN and its products, please visit www.itoen.com.
About ITO EN:
ITO EN (North America) INC., a subsidiary of ITO EN (Japan) LTD., is an innovative beverage industry leader dedicated to creating authentic products that embody the company’s five principles of Natural, Healthy, Safe, Well-designed and Delicious. With over 50 years of tea expertise in Japan, ITO EN is dedicated to authenticity, preserving its culture while creating global innovation, making it known as Japan’s #1 green tea purveyor with award-winning brands, including TEAS’ TEA Organic®, Oi Ocha®, ITO EN Shots® and matcha LOVE®. ITO EN’s strong commitment to social and environmental impact manifests in its partnerships with regional farmers and governments to stimulate local economies, development of sustainable procurement practices and nurture a new generation of tea farming. To learn more about ITO EN, visit www.itoen.com. ‘Like’ us on Facebook or follow us on Twitter and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190730005425/en/
Contact information
Rona Tison
ITO EN (North America) INC.
rtison@itoen.com
T. 707-327-6413
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom